Cantor Fitzgerald Investment Advisors L.P. Sells 25,873 Shares of Pfizer Inc. (NYSE:PFE)

Cantor Fitzgerald Investment Advisors L.P. trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 527,002 shares of the biopharmaceutical company's stock after selling 25,873 shares during the period. Cantor Fitzgerald Investment Advisors L.P.'s holdings in Pfizer were worth $13,981,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. State Street Corp boosted its position in Pfizer by 1.2% during the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after acquiring an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Geode Capital Management LLC grew its stake in Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. Finally, Swiss National Bank lifted its position in Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after buying an additional 100,900 shares during the period. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Finally, Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Stock Performance

PFE traded down $0.34 during midday trading on Tuesday, hitting $25.53. 36,520,039 shares of the company traded hands, compared to its average volume of 38,701,305. The company's 50-day moving average is $26.28 and its 200 day moving average is $27.69. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a market capitalization of $144.69 billion, a PE ratio of 18.11, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the company posted $0.10 earnings per share. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.74%. Pfizer's dividend payout ratio is currently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.